Year: 2025

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech litigation issued in September 2025 Additional analysis of imdusiran (AB-729) clinical data shows:– 46% of Phase 2a patients met criteria to discontinue all treatment– 94% of long-term follow-up patients remain off all treatment for up to 2+ years– 100% of HBV DNA positive patients in Phase 1b achieved HBV DNA levels belowquantification after only 18 weeks of imdusiran and nucleos(t)ide analogue therapy– All HBV e-antigen positive patients demonstrated dose-dependent HBV e-antigen decreases WARMINSTER, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation...

Dynacor Reports Record Sales and EBITDA in Q3-2025

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

MONTREAL, Nov. 13, 2025 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the “Corporation”) today announced its unaudited financial and operational results1 for the third quarter ended September 30, 2025. “This was a solid third quarter that reflects our team’s resolve to deliver strong operational results that are more representative of the usual Dynacor performance,” said Jean Martineau, President & CEO. “Despite ore supply disruptions in the first two weeks in the quarter, we are well on track to meet or beat our full-year production and financial guidance. The higher gold prices and consistent mill performance generated a number of new financial records including record quarterly EBITDA. With our strong cash flow generation and strengthened management team, we continue to cultivate shareholder value through...

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval Pathway in OngoingVERSATILE-003 Phase 3 Trial Design Conference Call and Webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business update, reported financial results for the third quarter ended September 30, 2025, and provided a clinical programs update. “Our request to meet with the FDA to propose an amendment to our ongoing VERSATILE-003 Phase 3 trial represents the culmination of the...

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026 CNTY-308 advancing through IND-enabling studies to support planned clinical study initiation in 2026 Estimated cash runway into 4Q 2027PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “Today we announced our iPSC derived beta islet program for T1D. We have generated a compelling preclinical data package that underscores the tremendous opportunity...

Intchains Group Limited To Acquire a Proof-of-Stake Technology Platform, and Expand Blockchain Infrastructure Capabilities

Written by Customer Service on November 13, 2025. Posted in Mergers And Acquisitions.

Acquisition adds staking operations for four prominent blockchains: Ethereum (ETH), Avalanche (AVAX), Manta (MANTA), and Conflux (CFX) SINGAPORE, Nov. 13, 2025 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), a company engaged in the provision of altcoin mining products, strategic acquisition and holding of Ethereum-based cryptocurrencies, and active development of innovative Web3 applications, today announced the signing of a definitive agreement to acquire a Proof-of-Stake (“PoS”) technology platform for $1.3 million, from ECHOLINK Limited (the “Seller”). The PoS platform, which is currently operated by DxPool, upon completion of the acquisition, will become an independent offering under Intchains and will be operating with a new brand identity. The acquisition is expected to close in approximately...

Aebi Schmidt Group achieves significant step-up in profitability following the integration of the Shyft Group; strong order momentum and continued backlog growth

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

Very strong order momentum, with third quarter order intake up 33% year-over-year Order backlog increased by another 6% since June 2025, supporting 2026 growth ambitions Group net sales of $471m, up 3% year-over-year, with expected significant growth in fourth quarter Adjusted EBITDA1 of $42.2m or 9.0% adjusted EBITDA margin, up 25% year-over-year with a 160 basis-point margin improvement Synergies materialization accelerated, supporting upper end of increased target of $40mFRAUENFELD, Switzerland,, Nov. 13, 2025 (GLOBE NEWSWIRE) — Aebi Schmidt Group (NASDAQ: AEBI) (“Aebi Schmidt” or the “Company”), a world-class specialty vehicles leader, reports significant step-up in profitability following the acquisition of the Shyft Group. “The entire new Aebi Schmidt Group has been focusing on executing the integration and realizing the...

KP Tissue Releases Third Quarter 2025 Financial Results

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

Accelerating profitable growth and building a new TAD tissue facility to start-up in 2028 MISSISSAUGA, Ontario, Nov. 13, 2025 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q3 2025 financial and operational results of KPT and Kruger Products Inc. (Kruger Products or the Company). Kruger Products is Canada’s leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and Bonterra®) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 12.1% interest in Kruger Products. Kruger Products Q3 2025 Business and Financial HighlightsRevenue was $561.1 million in Q3 2025 compared to $521.1 million in Q3 2024, an increase...

Venus Concept Announces Third Quarter 2025 Financial Results

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2025. Summary of Financial Results & Recent Progress:Energy Based Device (“EBD”) revenues showing signs of stabilization.Total EBD systems sales of $9.6 million, up 2% year over yearTotal revenue for the third quarter of $13.8 million, down 8% year-over-year and down 12% quarter-over-quarter.Primarily driven by a decline in the Hair Restoration business (the “Venus Hair Business”) impacted by a delay in the pending sale.Third quarter GAAP net loss of $22.5 million, compared to $9.3 million last year. Excluding loss on debt extinguishment, loss on disposal of subsidiaries and restructuring...

Broadwind Announces Third Quarter 2025 Results

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

CICERO, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) — Broadwind (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the third quarter 2025. THIRD QUARTER 2025 RESULTS(As compared to the third quarter 2024)Total revenue of $44.2 million, +25% y/y GAAP net income of $7.5 million, or $0.32 per diluted share Non-GAAP Adjusted EBITDA of $2.4 million, excluding the $8.2 million gain on the sale of industrial fabrication operations on September 8, 2025 Total orders of $43.6 million, +90% y/y Raising full-year 2025 revenue guidanceMANAGEMENT COMMENTARY “This year, our team continued to transform Broadwind into a leading precision manufacturing partner of choice to global OEMs,” stated Eric Blashford, President and CEO of Broadwind....

Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

Written by Customer Service on November 13, 2025. Posted in Earnings Releases And Operating Results.

Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential to Convert ‘Cold’ to ‘Hot’ Tumors, Supporting a Frontline Therapy Across the Bladder Cancer Spectrum; Phase 1b/2 Trial is on Track for Data Mid-2026 BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the third quarter ended September 30, 2025, and provided recent business highlights. “In the third quarter, we remained focused on clinical execution in both our global Phase 3 CoMpass trial in early choroidal melanoma and our Phase 1b/2 trial in NMIBC,”...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals